Protana Inc., successor to the business of MDS Proteomics Inc., offers an integrated suite of leading-edge technologies - protein identification, protein interaction mapping, differential analysis, phosphoprofiling, chemical proteomics, bioinformatics, small molecule hit discovery and lead optimization- that can be applied across the entire drug discovery and development process.
Protana's combination of world-class experts and sophisticated technology is committed to providing the global medical community and biopharmaceutical industry with leading-edge solutions for the diagnosis and treatment of disease.
Protana is one of the world's leading experts in the mass spectrometry analysis of proteins. The company has published studies in Nature, Nature Biotechnology, and Proceedings of the National Academy of Sciences. Protana Inc. has been recognized as a Technology Pioneer by the World Economic Forum and was the recipient of the prestigious 2005 Frost and Sullivan Growth Strategy Leadership Award.
The information on this and/or any other page on this website is subject to change without notice. Any use of this website is subject to the policies, disclaimers, and conditions set by Protana Inc. Please read our terms of use and legal notice.
